Literature DB >> 10555148

Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

J O Lee1, H Yang, M M Georgescu, A Di Cristofano, T Maehama, Y Shi, J E Dixon, P Pandolfi, N P Pavletich.   

Abstract

The PTEN tumor suppressor is mutated in diverse human cancers and in hereditary cancer predisposition syndromes. PTEN is a phosphatase that can act on both polypeptide and phosphoinositide substrates in vitro. The PTEN structure reveals a phosphatase domain that is similar to protein phosphatases but has an enlarged active site important for the accommodation of the phosphoinositide substrate. The structure also reveals that PTEN has a C2 domain. The PTEN C2 domain binds phospholipid membranes in vitro, and mutation of basic residues that could mediate this reduces PTEN's membrane affinity and its ability to suppress the growth of glioblastoma tumor cells. The phosphatase and C2 domains associate across an extensive interface, suggesting that the C2 domain may serve to productively position the catalytic domain on the membrane.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555148     DOI: 10.1016/s0092-8674(00)81663-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  409 in total

1.  Phosphorylation of the PTEN tail regulates protein stability and function.

Authors:  F Vazquez; S Ramaswamy; N Nakamura; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

2.  Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.

Authors:  N Nakamura; S Ramaswamy; F Vazquez; S Signoretti; M Loda; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Structure and mechanism of the RNA triphosphatase component of mammalian mRNA capping enzyme.

Authors:  A Changela; C K Ho; A Martins; S Shuman; A Mondragón
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

4.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

5.  Hypoxia induces cardiac fibroblast proliferation and phenotypic switch: a role for caveolae and caveolin-1/PTEN mediated pathway.

Authors:  Yao Gao; Ming Chu; Jian Hong; Jingping Shang; Di Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

6.  Understanding the stereospecific interactions of 3-deoxyphosphatidylinositol derivatives with the PTEN phosphatase domain.

Authors:  Qin Wang; Yang Wei; Madhusoodanan Mottamal; Mary F Roberts; Goran Krilov
Journal:  J Mol Graph Model       Date:  2010-05-20       Impact factor: 2.518

7.  PTEN controls tumor-induced angiogenesis.

Authors:  S Wen; J Stolarov; M P Myers; J D Su; M H Wigler; N K Tonks; D L Durden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

8.  C2 domains of protein kinase C isoforms alpha, beta, and gamma: activation parameters and calcium stoichiometries of the membrane-bound state.

Authors:  Susy C Kohout; Senena Corbalán-García; Alejandro Torrecillas; Juan C Goméz-Fernandéz; Joseph J Falke
Journal:  Biochemistry       Date:  2002-09-24       Impact factor: 3.162

9.  Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain.

Authors:  Joseph J Falke
Journal:  Cellscience       Date:  2007

10.  PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.

Authors:  Xiao-Ping Zhou; Anu Loukola; Reijo Salovaara; Minna Nystrom-Lahti; Päivi Peltomäki; Albert de la Chapelle; Lauri A Aaltonen; Charis Eng
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.